I saw an uplifting article in the Washington Post today regarding advances in adoptive cell therapy, including tumor-infiltrating lymphocytes (TILs as we know it) at NIH. Sorry - I don't know how to link the article.
But, guess what? Our very own Sleen (Celine) is named in the article as being the "first successful targeting of a deadly mutation called KRAS, which is implicated not only in colon cancers but in pancreatic and lung cancers". Incredible result with dramatic future implications.
I literally remember when Celine started her posts regarding this trial, and she was thoughtful and gracious during an incredibly difficult and uncertain time to take us on her journey through the process via her posts. (See her Topic posts). So, congratulations for being NED and thank you, Celine, for partaking in the clinical trial that will hopefully lead to developments that will bring relief to hundreds of thousands of people in the future!